IJFANS INTERNATIONAL JOURNAL OF FOOD AND NUTRITIONAL SCIENCES
ISSN PRINT 2319 1775 Online 2320 7876
Research Paper © 2012 IJFANS. All Rights Reserved Journal Volume 11, Iss 07, 2022

Automated Drug Discovery and Design Using Artificial Intelligence in Pharmacy

[1]Jaswinder Singh, [2]Dhruv Kumar, [3]Ashwani Sethi
Guru Kashi University[1,3], Talwandi Sabo, GNE College[2], Ludhiana

Abstract

Medication Discovery and Design Automation It is a novel idea to transform the conventional drug development method by utilizing artificial intelligence in pharmacy. In this study, we examine how artificial intelligence (AI) and pharmacy are combining, examining the ways in which AI technologies are changing the field of pharmaceutical research and development. We go over the basic ideas of artificial intelligence (AI), its numerous uses in drug discovery, and the possible advantages it could have for the pharmaceutical sector. We demonstrate how artificial intelligence (AI) may shorten the time it takes to identify new drugs, improve lead compound screening, and improve drug property prediction modelling by thoroughly examining the body of current research and case studies. We also look at the benefits and difficulties that come with integrating AI in pharmacy, including the ethical and legal ramifications. All things considered, this work offers insightful information about the revolutionary potential of AI-driven methods for automating drug discovery and design procedures, hence opening the door for more effective and efficient pharmacological interventions.

Keywords: *Automated Drug Discovery, Artificial Intelligence, Pharmacy, Drug Design, Machine Learning, Computational Drug Discovery*

1. INTRODUCTION

Intelligence and artificial intelligence are the two words that make up the term "artificial intelligence. "as a result of the fact that "man-made" is defined by Artificial, and "thinking power" is defined by Intelligence, the term "AI" refers to "a man-made thinking power[1]. "It is a subfield of computer science that allows for the creation of intelligent machines that are capable of acting in a manner similar to that of humans and which are also able to make judgments. The term "artificial intelligence" refers to the ability of machines to execute tasks that are typically performed by humans, such as learning, thinking, and problem-solving. Artificial intelligence (AI) gives a computer program the ability to think and learn automatically. The term "artificial intelligence" refers to the process of imitating human intelligence in robots in order to do tasks of which we would ordinarily rely on humans. The capabilities of artificial intelligence can be broken down into three primary categories: weak AI, strong AI, and super AI. Weak artificial intelligence is characterized by its ability to concentrate on a single task and its inability to function beyond its restrictions (which are typical in our everyday lives). AI that is strong is capable of understanding and learning any intellectual endeavour that a human being is capable of (researchers are working toward the goal of developing strong AI)[2]. "Super AI" refers to artificial intelligence that is superior to human intelligence and is capable of doing any task more effectively than a person (this concept is still in its infancy). In the field of artificial intelligence, John Mc Carthy is widely regarded

ISSN PRINT 2319 1775 Online 2320 7876
Research Paper © 2012 IJFANS. All Rights Reserved Journal Volume 11, Iss 07, 2022

as the pioneering figure. Together with Alan Turing, Marvin Minsky, Allen Newell, and Herbert A. Simon, he is considered to be one of the earliest pioneers in the field of artificial intelligence[3]. The first instances of intelligent robots and artificial entities can be traced back to the stories presented in Greek literature. In addition, the development of the syllogism and the application of deductive reasoning by Aristotle was a significant turning point in the development of humanity's quest to comprehend its own intelligence. In spite of having such deep and extensive roots, the history of artificial intelligence as we know it today stretches back to less than a century. INSO18-055 is the first medicine to have both a novel AI-discovered and a novel AI-generated design, in contrast to other AI-produced drugs that are currently being tested in clinical trials. On the Clinical Trials Database maintained by Global Data, there are six trials affiliated with In Silico Medicine[4]. Through the work of Professor H.N. Mahabala in the 1960s, artificial intelligence made its way into India. The United Nations Development Program (UNDP) developed Knowledge-Based Computing Systems (KBCS) in the year 1986. Artificial intelligence is putting a revolution in drug research by speeding up the process and improving the results. A tremendous amount of data is analyzed by machine learning algorithms in order to make predictions about prospective drug candidates, simulate chemical interactions, and locate molecules that have the potential to be therapeutic. The acceleration of the identification of interesting compounds, the reduction of expenses, and the enhancement of the efficiency of drug development are all associated with this. Artificial intelligence (AI) is utilized in the field of medicinal chemistry for the purpose of predicting the efficacy and toxicity of new potential therapeutic compounds. Traditional methods of drug development usually involve conducting tests that require a significant amount of time and effort in order to analyze the potential effects that a molecule may have on the human body. Artificial intelligence speeds up the process of drug discovery by doing away with the need for trial and error, empowering researchers to make judgments based on data, and improving the effectiveness of the process of generating new medicines [5].

1.1 Research and Discovery

The early stages of research and discovery are characterized by a sequence of key events, which may be seen in Figure 1. These events include the identification and validation of therapeutic targets, the identification of lead compounds, and the optimization of a lead chemical in order to select a development candidate [6].



Figure 1: Early Research and Discovery Process

- **Target Identification and Validation**

A macromolecular entity that is responsible for carrying out a biological function, such as a gene or a protein, is referred to as a pharmacological target. In the context of a disease, it has a

particular implication, and medications are molecules or ligands that attach to certain targets within the body [7]. Initial steps in the process of drug target discovery involve determining the functions of possible therapeutic targets, which may include proteins or genes. In the course of their work, researchers frequently discover potential therapeutic targets through academic study, scientific publications, or the mining of bioinformatics data. Data mining in bioinformatics has the capability to do selection and prioritization, and as advancements in artificial intelligence (AI) approaches become available, the process may undergo significant development [8].

It is necessary for molecular targets to demonstrate their functional relevance in triggering the onset or course of a disease after they have been identified and selected. The process of target validation involves the development of experimental models and assays for the purpose of screening and evaluating the pharmacological relation to the disease. This iterative process is anticipated to grow more widespread and frequent, which will ultimately result in the creation of drugs that are more efficient, less expensive, and more effective. Citalopram, lisinopril, and rivaroxaban are a few examples of medications that were derived from certain families of GPCR proteins.

- **Lead Compound Screening**

One definition of a lead compound is a novel chemical that possesses a particular biological or pharmacological function and has the potential to be developed into a treatment for the condition that is being discussed. Researchers design assays to screen presumptive series of chemicals or small molecules, and then experiment with a variety of methods and technologies throughout those screens. This allows them to identify how the target interacts with the compound or small molecule. A smaller selection of molecules is then chosen for further examination based on their capacity to actively interact with the target. High-throughput screening, often known as HTS, and targeted or knowledge-based screening are two of the most effective experimental screening technologies present today. In order to match the drug-like qualities, HTS uses automated robotics to execute millions of assays in a short amount of time. This is done with enormous libraries of compounds taking into account that there is no prior knowledge about the compounds. In the process of focused screening, compounds are narrowed down to a smaller group that may have specific prior-known activity with the therapeutic target. This can be determined through analysis of patent precedents or literature.

- **Lead Compound Optimization**

For the purpose of optimizing the characteristics of lead compounds, researchers often go through iterative rounds of synthesis and characterization. During these iterations, the developers record detailed measurements of the degree to which each core component is selective and active with respect to the target protein in comparison to other proteins that are not the target. They will choose the compound that binds to the target the most enthusiastically to serve as the lead compound.

The process of optimization involves testing not only the potency and selectivity of the compounds, but also their toxicity, safety, molecular mechanism, and dispersion. In the event that a lead compound has any flaws, such as a low action intensity or specificity, incorrect pharmacokinetic properties, significant toxic side effects, or chemical or metabolic instability,

the developers will make additional modifications to the chemical structure in order to generate a development candidate that has balanced properties.

2. LITERATURE REVIEW

Paul et al. (2021) [9] explored the application of artificial intelligence (AI) in drug discovery and development. The authors delved into various aspects of this field, aiming to provide insights into the then-current state of AI technologies and their impact on the pharmaceutical industry. Through a comprehensive analysis of existing literature, they elucidated the role of AI in accelerating drug discovery processes, optimizing drug design, and enhancing decision-making in drug development. Additionally, the review discussed the potential of AI-driven approaches in addressing challenges such as high attrition rates, lengthy development timelines, and rising costs associated with traditional drug discovery methods. By synthesizing findings from diverse studies and research initiatives, Paul et al. offered valuable perspectives on the transformative potential of AI in revolutionizing drug discovery and development paradigms, ultimately contributing to the advancement of therapeutic interventions for various diseases.

Stephenson et al. (2019) [10] surveyed machine learning techniques employed in drug discovery. The authors examined various machine learning approaches utilized in the field, aiming to provide an overview of the then-existing landscape of computational methods for drug discovery. Through an analysis of current research and applications, they highlighted the diversity of machine learning algorithms utilized for tasks such as compound screening, target prediction, and molecular property prediction. Additionally, the review discussed the advantages and limitations of different machine learning techniques in the context of drug discovery, shedding light on their potential contributions to accelerating the drug development process. By synthesizing insights from a range of studies, Stephenson et al. offered valuable perspectives on the role of machine learning in facilitating the identification and optimization of potential drug candidates, thereby advancing pharmaceutical research and innovation.

Deng et al. (2022) [11] examined the applications and techniques of artificial intelligence (AI) in drug discovery. The authors conducted a comprehensive review to explore the diverse applications of AI methodologies in various stages of the drug discovery process. Through their analysis, they elucidated the role of AI in accelerating drug discovery timelines, improving target identification, facilitating molecular design, and enhancing predictive modeling for drug properties. The review discussed a range of AI techniques, including machine learning algorithms, deep learning models, natural language processing (NLP), and computer vision, highlighting their respective strengths and limitations in the context of drug discovery. Furthermore, Deng et al. provided insights into the integration of AI with experimental and computational approaches, emphasizing the potential synergies for more efficient and effective drug discovery workflows. By synthesizing findings from recent studies and advancements in the field, the authors offered valuable perspectives on the transformative impact of AI technologies in revolutionizing drug discovery methodologies and driving innovation in pharmaceutical research.

Walters and Barzilay (2021) [12]conducted a critical assessment of artificial intelligence (AI) in the realm of drug discovery. Their expert opinion aimed to evaluate the current landscape of

IJFANS International Journal of Food And Nutritional Sciences

ISSN PRINT 2319 1775 Online 2320 7876
Research Paper © 2012 IJFANS. All Rights Reserved Journal Volume 11, Iss 07, 2022

AI applications within drug discovery, scrutinizing both its successes and limitations. Through a thorough analysis, the authors provided nuanced insights into the efficacy of AI methodologies across various stages of the drug discovery process. They examined the role of AI in target identification, compound screening, molecular design, and predictive modelling, shedding light on the challenges and opportunities inherent in each application. Additionally, Walters and Barzilay offered a nuanced perspective on the reliability and interpretability of AI-driven predictions, highlighting the importance of robust validation and transparency in AI models. Their critical assessment underscored the need for careful consideration of AI's capabilities and constraints in drug discovery endeavors, emphasizing the importance of collaborative efforts between AI researchers, domain experts, and pharmaceutical industry stakeholders.

3. AI IN DISEASE DIAGNOSIS

For the purpose of developing effective treatments and ensuring the health of patients, disease analysis is absolutely necessary [13]. Because human error and incorrect interpretation of information can impede accurate diagnosis, artificial intelligence has become an indispensable tool in the field of healthcare. Existing incongruities are being addressed through the development of new approaches, which are being developed in response to the growing need for healthcare. Artificial intelligence can be utilized to classify individuals according to the severity of their ailment, which enables rapid diagnosis. Maintaining patient health reports is recommended to collect reviews from examinations and testing. Through the use of artificial intelligence, early predicted stages of diseases can be identified, allowing for early treatment and improved efficiency. The identification, extraction, and administration of data are becoming increasingly difficult to accomplish without the utilization of deep learning, neural networking, and algorithms.

AI has become increasingly important in the treatment of cancer and dementia. It is impossible for algorithms to be biased if they are not self-generated or if they have never been correlated with any data that already exists. However, statistical monitoring necessitates the use of a dataset that is both pertinent and specific [14]. It is possible to obtain deep learning correlations by altering predictions and undergoing evolutionary changes. Additionally, larger data sets can be utilized to service the applicability of artificial intelligence. The diagnosis of dermatological illnesses and the identification of atrial fibrillation are also areas that make use of deep learning. A random splitting into different sets for the purpose of algorithm estimation can be accomplished through the use of cross-validation. There are three essential components of artificial intelligence: accuracy, sensitivity, and specificity. Sustained supervision of clinical features is possible through the utilization of support vector machines, closest neighbor, and various other techniques.

ISSN PRINT 2319 1775 Online 2320 7876
Research Paper © 2012 IJFANS. All Rights Reserved Journal Volume 11, Iss 07, 2022

Figure 2: AI in Disease Diagnosis

4. PREDICTIVE MODELING TECHNIQUES IN DRUG DESIGN ENCOMPASS VARIOUS METHODOLOGIES

Before potential drug candidates are synthesized and tested in the laboratory, predictive modeling in drug design refers to the use of computer approaches to anticipate certain features and behaviors of potential drug candidates[15]. This is done before the candidates are actually tested. In order to examine massive datasets that contain information about chemical structures, biological activities, and pharmacological qualities, this method makes use of mathematical and statistical models, which are frequently based on machine learning methods.

In the field of drug design, the primary objective of predictive modeling is to prioritize and optimize drug candidates by forecasting their efficacy, safety, pharmacokinetics, and other features that are pertinent to the design of medicine. Researchers are able to concentrate their efforts on compounds that have the highest probability of being successful if they are able to reliably forecast these qualities at an early stage in the process of drug development. This allows them to reduce the amount of time, money, and risk that is associated with the traditional trial-and-error methods.

In the field of drug discovery, predictive modeling techniques encompass a wide range of methodologies, including the following:

- **Quantitative Structure-Activity Relationship (QSAR) modelling**

The quantitative structure-activity relationship (QSAR) models allow researchers to anticipate the potency and selectivity of new drug candidates by correlating the chemical structure properties of molecules with their biological activities.

- **Pharmacophore modelling**

In order to assist in the development of novel compounds that possess the pharmacological qualities that are desired, pharmacophore models are utilized to determine the critical structural and spatial characteristics that are necessary for a molecule to interact with a biological target.

- **Molecular docking and virtual screening**

In order to estimate the binding affinity and binding mode of possible therapeutic candidates, molecular docking algorithms model the binding interactions that occur between small molecules and target proteins. Virtual screening is a process that involves the use of computational methods to search through huge chemical libraries in order to locate compounds that have the highest probability of binding to a particular target.

ISSN PRINT 2319 1775 Online 2320 7876
Research Paper © 2012 IJFANS. All Rights Reserved Journal Volume 11, Iss 07, 2022

- **Quantitative Structure-Property Relationship (QSPR) modelling**

In order to assist in the optimization of drug-like qualities, QSPR models are utilized to provide predictions regarding a variety of physicochemical and pharmacokinetic features of molecules. These properties include solubility, permeability, and metabolic stability.

- **Machine learning-based models**

It is possible to train machine learning techniques, including as support vector machines, random forests, and neural networks, using vast datasets of chemical and biological data in order to make predictions about a variety of drug-related features and activities. In general, predictive modeling in drug design plays an important part in guiding decision-making across the whole process of drug discovery. This includes everything from the selection and optimization of compounds to the creation of preclinical applications and clinical trials. The process of identifying and developing new therapeutic medicines is sped up by predictive modeling because it enables researchers to make judgments that are educated and based on computational predictions.

5. Conclusion

Significant progress has been made in the field of drug design and discovery by artificial intelligence (AI). Target identification, lead compound screening, and predictive modeling are just a few of the phases of the drug development process that are being streamlined by the rising use of AI techniques like machine learning and deep learning. Drug discovery efforts are now more accurate, efficient, and cost-effective as a result of the integration of AI technologies. Additionally, the data provides particular instances of how AI has impacted drug discovery, such as the creation of INSO18-055, the first medication with both a novel AI-generated and -discovered design. AI has also proved crucial in processing massive amounts of data to simulate chemical interactions, forecast potential medication candidates, and increase the effectiveness of drug research. To sum up, the application of artificial intelligence to medication design and discovery is a major development for the pharmaceutical sector. AI-driven strategies have the potential to alleviate issues with conventional drug discovery techniques, including high attrition rates, protracted development schedules, and growing costs. AI technologies are expected to become more and more important in advancing therapeutic approaches for a range of diseases as they develop.

REFERENCES

1. Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021). Artificial intelligence to deep learning: machine intelligence approach for drug discovery. *Molecular diversity*, *25*, 1315-1360.'
2. Vora, L. K., Gholap, A. D., Jetha, K., Thakur, R. R. S., Solanki, H. K., & Chavda, V. P. (2023). Artificial intelligence in pharmaceutical technology and drug delivery design. *Pharmaceutics*, *15*(7), 1916.
3. Brown, N., Ertl, P., Lewis, R., Luksch, T., Reker, D., & Schneider, N. (2020). Artificial intelligence in chemistry and drug design. *Journal of Computer-Aided Molecular Design*, *34*, 709-715.

ISSN PRINT 2319 1775 Online 2320 7876
Research Paper © 2012 IJFANS. All Rights Reserved Journal Volume 11, Iss 07, 2022

4. Jiménez-Luna, J., Grisoni, F., Weskamp, N., & Schneider, G. (2021). Artificial intelligence in drug discovery: recent advances and future perspectives. *Expert opinion on drug discovery*, *16*(9), 949-959.
5. Yang, X., Wang, Y., Byrne, R., Schneider, G., & Yang, S. (2019). Concepts of artificial intelligence for computer-assisted drug discovery. *Chemical reviews*, *119*(18), 10520-10594.
6. Hessler, G., & Baringhaus, K. H. (2018). Artificial intelligence in drug design. *Molecules*, *23*(10), 2520.
7. Sarkar, C., Das, B., Rawat, V. S., Wahlang, J. B., Nongpiur, A., Tiewsoh, I., ... & Sony, H. T. (2023). Artificial intelligence and machine learning technology driven modern drug discovery and development. *International Journal of Molecular Sciences*, *24*(3), 2026.
8. Schneider, P., Walters, W. P., Plowright, A. T., Sieroka, N., Listgarten, J., Goodnow Jr, R. A., ... & Schneider, G. (2020). Rethinking drug design in the artificial intelligence era. *Nature Reviews Drug Discovery*, *19*(5), 353-364.
9. Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R. K. (2021). Artificial intelligence in drug discovery and development. *Drug discovery today*, *26*(1), 80.
10. Schneider, G. (2018). Automating drug discovery. *Nature reviews drug discovery*, *17*(2), 97-113.
11. KALAYIL, N. V., D'SOUZA, S. S., KHAN, S. Y., & PAUL, P. (2022). ARTIFICIAL INTELLIGENCE IN PHARMACY DRUG DESIGN. *ARTIFICIAL INTELLIGENCE*, *15*(4).
12. Das, S., Dey, R., & Nayak, A. K. (2021). Artificial intelligence in pharmacy. *Indian Journal of Pharmaceutical Education and Research*, *55*(2), 304-318.
13. Chopra, H., Baig, A. A., Gautam, R. K., & Kamal, M. A. (2022). Application of Artificial intelligence in Drug Discovery. *Current Pharmaceutical Design*, *28*(33), 2690-2703.
14. Sayam, A. G., Pradhan, M., & Choudhury, A. K. (2023). Artificial Intelligence the Futuristic Technology in the Drug Discovery Process: A Review. *Journal of Young Pharmacists*, *15*(3), 390-396.
15. Shiammala, P. N., Duraimutharasan, N. K. B., Vaseeharan, B., Alothaim, A. S., Al-Malki, E. S., Snekaa, B., ... & Selvaraj, C. (2023). Exploring the Artificial Intelligence and Machine Learning Models in the Context of Drug Design Difficulties and Future Potential for the Pharmaceutical Sectors. *Methods*.